COVID-19 Coronavirus Infection Risk May be Reduced by Weekly Dose of Vitamin D3
Support for Vitamin D and infections:
- Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data https://www.bmj.com/content/356/bmj.i6583
- Former Center for Disease Control, (“CDC”) Chief Dr.
Tom Frieden talks: Coronavirus infection risk may be reduced by Vitamin D https://www.foxnews.com/opinion/former-cdc-chief-tom-frieden-coronavirus-risk-may-be-reduced-with-vitamin-d
50,000 IU of Vitamin D3 is ideal for:
- People who have difficulty achieving and maintaining peak vitamin D levels
- Elderly patients with low vitamin D levels
- Overweight patients with an elevated body mass index that impairs vitamin D circulation requiring significant repletion doses
Vitamin D3 has been shown to:
- Prevent respiratory infections
- Maintain bone and dental health
- Increase calcium absorption and balance
- Boost immune activity
- Support cardiometabolic health, blood sugar balance already within normal levels, and weight loss
- Help increase musculoskeletal strength and comfort
CUREfilm® D offers the following advantages:
- Uses Cholecalciferol, the ideal form found to maintain active vitamin D levels for an extended period of time
- High dose of 50,000 IU Vitamin D3 delivered via shelf-stable, individually sealed CUREfilm® technology for ease of use and maximum benefit
About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA- registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform's combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the US,
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.
About Parallax Health Sciences
Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our Form 10-K and other reports filed with the
Investor Contact:
paul@parallaxcare.com
cell 404-915-8449
SOURCE: Parallax Health Sciences, Inc.
Source:
2020 GlobeNewswire, Inc., source